Enanta Pharmaceuticals Expectations

• Expecting Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19
• The Firm Completed Enrollment in RSVP, a Phase 2b Conducted Trial of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV)
• Expects Topline Data in the Second Quarter of 2022
• The Firm has Plans to Initiate a Phase 1 Study of EDP-323, an RSV L-Protein Inhibitor in the Second Half of 2022

After studying its clinical trial results, ProhostBiotech . . .